Collegium Pharmaceutical Inc (COLL, Financial) has experienced a notable uptick in its stock performance, with a market capitalization now standing at $1.05 billion. The current price of $32.22 reflects a 3.38% gain over the past week and an impressive 37.21% gain over the past three months. According to the GF Value, which is currently at $29.75, Collegium Pharmaceutical is deemed to be fairly valued. This is a shift from three months ago when the stock was considered modestly undervalued with a past GF Value of $31.35.
Understanding Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc, operating within the drug manufacturers industry, is a specialty pharmaceutical company focused on the development and commercialization of abuse-deterrent products. Utilizing its patented DETERx platform technology, the company aims to treat chronic pain and other diseases while maintaining the safety profiles of highly abused drugs. Their product portfolio includes Xtampza ER, an extended-release formulation of oxycodone, and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol. 
Profitability Insights
Collegium Pharmaceutical's Profitability Rank stands at 4/10. The company's operating margin is an impressive 21.41%, ranking better than 86.99% of its peers. In terms of return on equity (ROE), the company's 4.74% is better than 52.08% of its peers. Additionally, the return on assets (ROA) at 0.75% and return on invested capital (ROIC) at 5.58% rank better than 46.9% and 58.9% of peers, respectively. Despite these strong figures, Collegium has only been profitable for 2 out of the past 10 years. 
Growth Trajectory
The company's Growth Rank is an impressive 7/10. Collegium has demonstrated a 3-Year Revenue Growth Rate per Share of 15.60%, outperforming 78.42% of its industry peers. The 5-Year Revenue Growth Rate per Share is even more remarkable at 43.70%, surpassing 95.73% of competitors. Looking ahead, the Total Revenue Growth Rate (Future 3Y To 5Y Est) is projected at 8.39%, which is better than 63.75% of peers. 
Top Shareholders
Notable investors have taken positions in Collegium Pharmaceutical, with Jim Simons (Trades, Portfolio) leading the pack holding 1,172,598 shares, representing a 3.6% share percentage. Joel Greenblatt (Trades, Portfolio) follows with 42,963 shares, equating to a 0.13% share percentage, and Chuck Royce (Trades, Portfolio) holds 21,230 shares, or 0.07% of the company.
Competitive Landscape
When compared to its closest competitors, Collegium Pharmaceutical stands strong. Avadel Pharmaceuticals PLC (AVDL, Financial) and Deciphera Pharmaceuticals Inc (DCPH, Financial) both have market capitalizations of $1.3 billion, indicating a highly competitive market within the drug manufacturing industry.
Conclusion
In summary, Collegium Pharmaceutical Inc's stock performance has been robust, with a significant 37.21% gain over the past three months. The company is currently fairly valued according to the GF Value. Collegium's profitability and growth prospects appear solid, with strong operating margins and revenue growth rates. The company also boasts a noteworthy roster of investors, including Jim Simons (Trades, Portfolio), Joel Greenblatt (Trades, Portfolio), and Chuck Royce (Trades, Portfolio). When juxtaposed with its competitors, Collegium holds its ground, suggesting a stable position within the market. Investors and stakeholders can be cautiously optimistic about the company's future trajectory based on these financial indicators.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
